Inhaled verapamil in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD)

Phase 1

Recruiting

• Conditions: Pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD); Respiratory - Chronic obstructive pulmonary disease

• Registration Number: ACTRN12612001239853
• Lead Sponsor: Shahid Beheshti University, M.C.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-11-23
• Last Update Posted: 2020-01-13

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with pulmonary arterial pressure (PAP)>45mmHg secondary to chronic obstructive pulmonary disease (COPD) and normal ejection fraction (EF) (> 40%).

Exclusion Criteria

1.Pregnancy 2.Patients with previous known hypersensitivity to verapamil (any formulation or route of administration) 3. Patients with sepsis 4. Patients with dysrythmia or heart block (second degree and third degree). 5.Patients with COPD exacerbation 6.Any contraindication for verapamil 7.Presence of an end stage disease (cardiac, renal and hepatic) 8.Patients receiving another calcium channel blocker (CCB), sildenafil and bosentan .

Study & Design

• Study Type: Interventional
• Study Design: Not specified